Loading
A Chinese study developing a low-cost DNA methylation blood test for several cancers that runs on ordinary PCR machines.
Pan-cancer plasma DNA methylation PCR test (NCT05685524) is an observational study sponsored by Wuhan Ammunition Life-tech Co., Ltd. It aims to identify plasma methylation markers for multi-cancer detection read by multiplex fluorescence PCR.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 17 January 2023), with an estimated 3,000 participants, a start on 1 July 2022 and primary completion expected in August 2023.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/